紫杉醇联合奥沙利铂与卡培他滨联合奥沙利铂治疗晚期胃癌的疗效比较

Comparison of curative effect in advanced gastric cancer patients treated with paclitaxel plus oxaliplatin and capecitabine plus oxaliplatin

目的观察并比较紫杉醇联合奥沙利铂与卡培他滨联合奥沙利铂治疗晚期胃癌的近期疗效与不良反应。方法回顾性分析54例晚期胃癌患者治疗情况,紫杉醇联合奥沙利铂组(A组)25例,卡培他滨联合奥沙利铂组(B组)29例。所有病例治疗4～8个周期后,评价其近期疗效及不良反应。结果近期疗效评价,A组有效率为44.0%,B组有效率为41.2%,两组比较差异无统计学意义(P>0.05)。主要不良反应为中性粒细胞减少、恶心呕吐、手足综合征、肝功能损害、外周神经毒性、脱发,其中A组中性粒细胞减少及脱发明显高于B组(P<0.05),B组手足综合征明显高于A组(P<0.05),其余不良反应两组差异无统计学意义(P>0.05),两组均无化疗相关性死亡。结论两种方案近期疗效相当,不良反应均可耐受,均值得临床选择应用。

Objective To investigate the curative effect and toxicity of paclitaxel plus oxaliplatin and capecitabine plus oxaliplatin in the treatment of advanced gastric cancer. Methods A total of 54 patients with advanced gastric cancer were retrospectively analyzed. Twenty-five cases were treated with paclitaxel plus oxaliplatin （Group A）, the other 29 cases were treated with capecitabine plus oxaliplatin （Group B）. The curative effect and toxicity of all patients were evaluated after treatment for 4- 8 chemotherapy cycles. Results The overall response rate was 44.0% in group A and 41.2% in group B. There was no statistical significance between the two groups （P〈0.05）. The main toxicities were neutropenia, nausea, vomiting, hand-foot syndrome, liver dysfunctions, peripheral nerve toxicity and alopecia. The incidence of neutropenia and alopecia were significantly higher in group A than in group B （P〈0.05）. While the incidence of hand-foot syndrome was significantly higher in group B than in group A （P〈（0.05）. There was no death related with chemotherapy in the two groups. Conclusion The study proves that paclitaxel plus oxaliplatin and capecitabine plus oxaliplatin are effective for advanced gastric cancer patients, which are worthy of further clinical applications.